{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T04:22:22Z","timestamp":1775881342786,"version":"3.50.1"},"reference-count":53,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>B-cell lymphoma 2 (Bcl-2) is a pivotal regulator of apoptotic cell death and it is overexpressed in many cancers. Consequently, the Bcl-2 protein is an attractive target for drug design, and Bcl-2\u2013specific antisense oligonucleotides or small-molecule Bcl-2 inhibitors have shown broad anticancer activities in preclinical models and are currently in several clinical trials. The clinical application of immunotherapy against cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti\u2013tumor-reactive T cells and the use of \u201ctherapeutic\u201d vaccines. The overexpression of Bcl-2 in cancer and the fact that immune escape by down-regulation or loss of expression of this protein would impair sustained tumor growth makes Bcl-2 a very attractive target for anticancer immunotherapy. Herein, we describe spontaneous T-cell reactivity against Bcl-2 in peripheral blood from patients suffering from unrelated tumor types (ie, pancreatic cancer, breast cancer, acute myeloid leukemia [AML], and chronic lymphocytic leukemia [CLL]). Additionally, we show that these Bcl-2\u2013reactive T cells are indeed peptide-specific, cytotoxic effector cells. Thus, Bcl-2 may serve as an important and widely applicable target for anticancer immunotherapeutic strategies (eg, in the combination with conventional radiotherapy and chemotherapy).<\/jats:p>","DOI":"10.1182\/blood-2004-07-2548","type":"journal-article","created":{"date-parts":[[2004,9,15]],"date-time":"2004-09-15T03:44:56Z","timestamp":1095219896000},"page":"728-734","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":52,"title":["Immunogenicity of Bcl-2 in patients with cancer"],"prefix":"10.1182","volume":"105","author":[{"given":"Mads Hald","family":"Andersen","sequence":"first","affiliation":[{"name":"From the Tumor Immunology Group, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark; Department of Hematology, Herlev University Hospital, Copenhagen, Denmark; Department of Hematology, State University Hospital, Copenhagen, Denmark; and Department of Dermatology, University of Wu\u0308rzburg, Wu\u0308rzburg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[{"name":"From the Tumor Immunology Group, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark; Department of Hematology, Herlev University Hospital, Copenhagen, Denmark; Department of Hematology, State University Hospital, Copenhagen, Denmark; and Department of Dermatology, University of Wu\u0308rzburg, Wu\u0308rzburg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia","family":"Kvistborg","sequence":"additional","affiliation":[{"name":"From the Tumor Immunology Group, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark; Department of Hematology, Herlev University Hospital, Copenhagen, Denmark; Department of Hematology, State University Hospital, Copenhagen, Denmark; and Department of Dermatology, University of Wu\u0308rzburg, Wu\u0308rzburg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ove Juul","family":"Nielsen","sequence":"additional","affiliation":[{"name":"From the Tumor Immunology Group, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark; Department of Hematology, Herlev University Hospital, Copenhagen, Denmark; Department of Hematology, State University Hospital, Copenhagen, Denmark; and Department of Dermatology, University of Wu\u0308rzburg, Wu\u0308rzburg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Balslev","sequence":"additional","affiliation":[{"name":"From the Tumor Immunology Group, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark; Department of Hematology, Herlev University Hospital, Copenhagen, Denmark; Department of Hematology, State University Hospital, Copenhagen, Denmark; and Department of Dermatology, University of Wu\u0308rzburg, Wu\u0308rzburg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sine","family":"Reker","sequence":"additional","affiliation":[{"name":"From the Tumor Immunology Group, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark; Department of Hematology, Herlev University Hospital, Copenhagen, Denmark; Department of Hematology, State University Hospital, Copenhagen, Denmark; and Department of Dermatology, University of Wu\u0308rzburg, Wu\u0308rzburg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju\u0308rgen C.","family":"Becker","sequence":"additional","affiliation":[{"name":"From the Tumor Immunology Group, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark; Department of Hematology, Herlev University Hospital, Copenhagen, Denmark; Department of Hematology, State University Hospital, Copenhagen, Denmark; and Department of Dermatology, University of Wu\u0308rzburg, Wu\u0308rzburg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per thor","family":"Straten","sequence":"additional","affiliation":[{"name":"From the Tumor Immunology Group, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark; Department of Hematology, Herlev University Hospital, Copenhagen, Denmark; Department of Hematology, State University Hospital, Copenhagen, Denmark; and Department of Dermatology, University of Wu\u0308rzburg, Wu\u0308rzburg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021222475673000_REF1","doi-asserted-by":"crossref","unstructured":"Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst. 2002;94: 805-818.","DOI":"10.1093\/jnci\/94.11.805"},{"key":"2020021222475673000_REF2","doi-asserted-by":"crossref","unstructured":"Machiels JP, van Baren N, Marchand M. Peptide-based cancer vaccines. Semin Oncol. 2002;29: 494-502.","DOI":"10.1053\/sonc.2002.35244"},{"key":"2020021222475673000_REF3","doi-asserted-by":"crossref","unstructured":"Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother. 2001;50: 3-15.","DOI":"10.1007\/s002620000169"},{"key":"2020021222475673000_REF4","doi-asserted-by":"crossref","unstructured":"Riker A, Cormier J, Panelli M, et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery. 1999;126: 112-120.","DOI":"10.1016\/S0039-6060(99)70143-1"},{"key":"2020021222475673000_REF5","doi-asserted-by":"crossref","unstructured":"Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine. 2002;19: A40-A45.","DOI":"10.1016\/S0264-410X(02)00386-9"},{"key":"2020021222475673000_REF6","doi-asserted-by":"crossref","unstructured":"Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev. 2001;35: 161-204.","DOI":"10.1016\/S0165-0173(01)00045-5"},{"key":"2020021222475673000_","doi-asserted-by":"crossref","unstructured":"Chen ZS, Aoki S, Komatsu M, et al. Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. Int J Cancer. 2001;93: 107-113.","DOI":"10.1002\/ijc.1290"},{"key":"2020021222475673000_","doi-asserted-by":"crossref","unstructured":"White MK, McCubrey JA. Suppression of apoptosis: role in cell growth and neoplasia. Leukemia. 2001;15: 1011-1021.","DOI":"10.1038\/sj.leu.2402143"},{"key":"2020021222475673000_REF9","doi-asserted-by":"crossref","unstructured":"Sun SY, Yue P, Zhou JY, et al. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun. 2001;280: 788-797.","DOI":"10.1006\/bbrc.2000.4218"},{"key":"2020021222475673000_REF10","unstructured":"Wittmann S, Bali P, Donapaty S, et al. Flavopiridol down-regulates anti-apoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res. 2003;63: 93-99."},{"key":"2020021222475673000_REF11","doi-asserted-by":"crossref","unstructured":"Zaffaroni N, Pennati M, Colella G, et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci. 2002;59: 1406-1412.","DOI":"10.1007\/s00018-002-8518-3"},{"key":"2020021222475673000_REF12","doi-asserted-by":"crossref","unstructured":"Reed JC. Bcl-2 family proteins. Oncogene. 1998; 17: 3225-3236.","DOI":"10.1038\/sj.onc.1202591"},{"key":"2020021222475673000_REF13","doi-asserted-by":"crossref","unstructured":"Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell. 1997;91: 443-446.","DOI":"10.1016\/S0092-8674(00)80430-4"},{"key":"2020021222475673000_REF14","doi-asserted-by":"crossref","unstructured":"Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med. 1997;3: 614-620.","DOI":"10.1038\/nm0697-614"},{"key":"2020021222475673000_REF15","doi-asserted-by":"crossref","unstructured":"Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol. 2002;13: 539-545.","DOI":"10.1093\/annonc\/mdf124"},{"key":"2020021222475673000_","doi-asserted-by":"crossref","unstructured":"Reed JC, Miyashita T, Takayama S, et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem. 1996;60: 23-32.","DOI":"10.1002\/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.0.CO;2-5"},{"key":"2020021222475673000_","unstructured":"Hua C, Raffeld M, Ko HS, et al. Mechanism of bcl-2 activation in human follicular lymphoma. Oncogene. 1990;5: 233-235."},{"key":"2020021222475673000_","doi-asserted-by":"crossref","unstructured":"Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Options Oncol. 2003;4: 211-218.","DOI":"10.1007\/s11864-003-0022-y"},{"key":"2020021222475673000_","doi-asserted-by":"crossref","unstructured":"Wang HG, Takayama S, Rapp UR, Reed JC. Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci U S A. 1996;93: 7063-7068.","DOI":"10.1073\/pnas.93.14.7063"},{"key":"2020021222475673000_REF20","doi-asserted-by":"crossref","unstructured":"Coultas L, Strasser A. The role of the Bcl-2 protein family in cancer. Semin Cancer Biol. 2003; 13: 115-123.","DOI":"10.1016\/S1044-579X(02)00129-3"},{"key":"2020021222475673000_REF21","doi-asserted-by":"crossref","unstructured":"Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22: 8590-8607.","DOI":"10.1038\/sj.onc.1207102"},{"key":"2020021222475673000_REF22","doi-asserted-by":"crossref","unstructured":"Pratt MA, Krajewski S, Menard M, et al. Estrogen withdrawal-induced human breast cancer tumour regression in nude mice is prevented by Bcl-2. FEBS Lett. 1998;440: 403-408.","DOI":"10.1016\/S0014-5793(98)01499-9"},{"key":"2020021222475673000_","unstructured":"Bonetti A, Zaninelli M, Leone R, et al. bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res. 1998;4: 2331-2336."},{"key":"2020021222475673000_REF24","doi-asserted-by":"crossref","unstructured":"Buchholz TA, Davis DW, McConkey DJ, et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 2003;9: 33-41.","DOI":"10.1097\/00130404-200301000-00007"},{"key":"2020021222475673000_REF25","doi-asserted-by":"crossref","unstructured":"Manion MK, Hockenbery DM. Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther. 2003;2: S105-S114.","DOI":"10.4161\/cbt.209"},{"key":"2020021222475673000_REF26","doi-asserted-by":"crossref","unstructured":"Andersen MH, Sondergaard I, Zeuthen J, Elliott T, Haurum JS. An assay for peptide binding to HLA-Cw*0102. Tissue Antigens. 1999;54: 185-190.","DOI":"10.1034\/j.1399-0039.1999.540210.x"},{"key":"2020021222475673000_REF27","doi-asserted-by":"crossref","unstructured":"McCutcheon M, Wehner N, Wensky A, et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods. 1997;210: 149-166.","DOI":"10.1016\/S0022-1759(97)00182-8"},{"key":"2020021222475673000_REF28","unstructured":"Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am. 1998;4: 316-323."},{"key":"2020021222475673000_REF29","doi-asserted-by":"crossref","unstructured":"Berke Z, Andersen MH, Pedersen M, et al. Peptides spanning the junctional region of both the abl\/bcr and the bcr\/abl fusion proteins bind common HLA class I molecules. Leukemia. 2000;14: 419-426.","DOI":"10.1038\/sj.leu.2401703"},{"key":"2020021222475673000_REF30","doi-asserted-by":"crossref","unstructured":"Rininsland FH, Helms T, Asaad RJ, Boehm BO, Tary-Lehmann M. Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. J Immunol Methods. 2000;240: 143-155.","DOI":"10.1016\/S0022-1759(00)00191-5"},{"key":"2020021222475673000_REF31","unstructured":"Andersen MH, Pedersen LO, Capeller B, et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001;61: 5964-5968."},{"key":"2020021222475673000_REF32","doi-asserted-by":"crossref","unstructured":"Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 2002;20: 143-148.","DOI":"10.1038\/nbt0202-143"},{"key":"2020021222475673000_REF33","doi-asserted-by":"crossref","unstructured":"Andersen MH, Bonfill JE, Neisig A, et al. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol. 1999;163: 3812-3818.","DOI":"10.4049\/jimmunol.163.7.3812"},{"key":"2020021222475673000_REF34","doi-asserted-by":"crossref","unstructured":"Andersen MH, Tan L, Sondergaard I, et al. Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens. 2000;55: 519-531.","DOI":"10.1034\/j.1399-0039.2000.550603.x"},{"key":"2020021222475673000_REF35","unstructured":"Andersen MH, Pedersen LO, Becker JC, thor Straten P. Identification of a cytotoxic T lymphocyte response to the apoptose inhibitor protein survivin in cancer patients. Cancer Res. 2001;61: 869-872."},{"key":"2020021222475673000_","doi-asserted-by":"crossref","unstructured":"Scheibenbogen C, Sun Y, Keilholz U, et al. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int J Cancer. 2002;98: 409-414.","DOI":"10.1002\/ijc.10205"},{"key":"2020021222475673000_REF37","doi-asserted-by":"crossref","unstructured":"Herr W, Ranieri E, Gambotto A, et al. Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc Natl Acad Sci U S A. 1999;96: 12033-12038.","DOI":"10.1073\/pnas.96.21.12033"},{"key":"2020021222475673000_REF38","doi-asserted-by":"crossref","unstructured":"Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 2002;25: 97-138.","DOI":"10.1097\/00002371-200203000-00001"},{"key":"2020021222475673000_REF39","doi-asserted-by":"crossref","unstructured":"Andersen MH, Reker S, Becker JC, thor Straten P. The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses. J Invest Dermatol. 2004;122: 392-399.","DOI":"10.1046\/j.0022-202X.2004.22242.x"},{"key":"2020021222475673000_","doi-asserted-by":"crossref","unstructured":"Andersen MH, Gehl J, Reker S, et al. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 amdministration. Semin Cancer Biol. 2003;13: 449-459.","DOI":"10.1016\/j.semcancer.2003.09.009"},{"key":"2020021222475673000_REF41","doi-asserted-by":"crossref","unstructured":"Reker S, Becker JC, Svane IM, et al. HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer. 2004;108: 937-941.","DOI":"10.1002\/ijc.11634"},{"key":"2020021222475673000_REF42","doi-asserted-by":"crossref","unstructured":"Shafer-Weaver K, Sayers T, Strobl S, et al. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med. 2003;1: 14.","DOI":"10.1186\/1479-5876-1-14"},{"key":"2020021222475673000_REF43","doi-asserted-by":"crossref","unstructured":"D'Souza S, Rimoldi D, Lienard D, et al. Circulating Melan-A\/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. Int J Cancer. 1998; 78: 699-706.","DOI":"10.1002\/(SICI)1097-0215(19981209)78:6<699::AID-IJC6>3.0.CO;2-U"},{"key":"2020021222475673000_","doi-asserted-by":"crossref","unstructured":"Ja\u0308ger E, Ringhoffer M, Arand M, et al. Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals. Melanoma Res. 1996;6: 419-425.","DOI":"10.1097\/00008390-199612000-00003"},{"key":"2020021222475673000_REF45","doi-asserted-by":"crossref","unstructured":"Griffioen M, Borghi M, Schrier PI, Osanto S. Detection and quantification of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay. Int J Cancer. 2001;93: 549-555.","DOI":"10.1002\/ijc.1361"},{"key":"2020021222475673000_REF46","unstructured":"Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6: 127-134."},{"key":"2020021222475673000_REF47","doi-asserted-by":"crossref","unstructured":"Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998;351: 882-883.","DOI":"10.1016\/S0140-6736(05)70294-4"},{"key":"2020021222475673000_REF48","unstructured":"Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998;58: 1808-1812."},{"key":"2020021222475673000_REF49","unstructured":"Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58: 5071-5074."},{"key":"2020021222475673000_REF50","doi-asserted-by":"crossref","unstructured":"Schmidt SM, Schag K, Muller MR, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood. 2003;102: 571-576.","DOI":"10.1182\/blood-2002-08-2554"},{"key":"2020021222475673000_","unstructured":"Casati C, Dalerba P, Rivoltini L, et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8(+) and CD4(+) T cells in colorectal cancer patients. Cancer Res. 2003;63: 4507-4515."},{"key":"2020021222475673000_","unstructured":"Pisarev V, Yu B, Salup R, et al. Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res. 2003;9: 6523-6533."},{"key":"2020021222475673000_REF53","doi-asserted-by":"crossref","unstructured":"Reker S, Meier A, Holten-Andersen L, et al. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther. 2004;3: 173-179.","DOI":"10.4161\/cbt.3.2.611"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/2\/728\/1705343\/zh800205000728.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/2\/728\/1705343\/zh800205000728.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T09:38:41Z","timestamp":1682761121000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/2\/728\/20056\/Immunogenicity-of-Bcl2-in-patients-with-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,15]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-07-2548","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,15]]}}}